ACAA

10.0500.00%
AM

Akiko Moni Miyashita

Director

Ms. Akiko Moni Miyashita is Director of Averin Capital Acquisition Corp. from May 28, 2026. Ms. Miyashita was Independent Director of Halozyme Therapeutics, Inc. from March 2022 to 2026. She had been Chief Strategy Officer of Valo Health, Inc. since May 2019. She serves as Director at Halozyme Inc. Ms. Miyashita has experience building companies through M&A and portfolio management, with a laser focus on value creation. As a Partner at Innosight from August 2015 to August 2019, (a firm co-founded by world-renowned disruptive innovation expert, Clay Christensen (HBS), she advised CEO's on solving their hardest problems of retaining industry leadership. She was with McKinsey & Company as Senior Advisor Merger Management from October 2011 to September 2015, to over 150 global CEO's and clients on their largest and most complex M&A transactions. Prior to McKinsey, she was Vice President of Corporate Development at IBM from July 2009 to October 2011 where she executed 125 acquisitions over a decade-long business transformation, doubling IBM’s market value. where she led mergers and acquisitions from strategy through integration, as well as strategic partnerships and venture investments across global markets. She served as Managing Director, M&A Integration of IBM from July 2003 to July 2009 and Director, Asia Pacific & Japan Corporate Development from December 1998 to July 2003. Ms. Miyashita served on the Boards of Children’s Hospital of Philadelphia, University of Denver, US-Japan Council and Biogen’s Advisory Board. She completed an MBA from the University of Denver - Daniels College of Business and a BS in Marketing from the University of Colorado Boulder - Leeds School of Business. She holds Executive Program, Global Women’s Executive Leadership Forum from 2007 to 2007 and Executive Programs, Succeeding as a Corporate Board Director from 2017 to 2017 at the Harvard Business School.

Positions